Children aged 1 to 11 years with eosinophilic esophagitis safely achieved histologic disease remission after 16 weeks of treatment with the fully human monoclonal antibody dupilumab, according to the results of a phase 3 trial.
Dupilumab (Dupixent, Sanofi Genzyme/Regeneron) inhibits the signaling of the IL-4 and IL-13 pathways, which drive type 2 inflammation. It is currently FDA approved for treating eosinophilic esophagitis in adults and children aged 12 years and older.
“Eosinophilic esophagitis can turn the basic and life-sustaining act of eating into a painful experience at a point